spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  receptor tyrosine kinase 

 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Nov 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 May 2020
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
Diagnostics Oncology FDA
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 15 Mar 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Biopharmaceuticals Oncology Urology FDA
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Dec 2016
Celldex Therapeutics Announces Appointment to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Mar 2016
FLAG Therapeutics Announces the Granting of Orphan Drug Designation to FLAG-003 in both the US and EU for the Treatment of Glioma
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology
 HSMN NewsFeed - 16 Jul 2015
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Diagnostics Personnel
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Aug 2014
Caris Molecular Intelligence(TM) Identifies Key Biomarkers of Clinical Benefit and Resistance to Chemotherapy through Multi-Technology Tumor Profiling
Diagnostics Oncology
 HSMN NewsFeed - 23 Apr 2014
Kala Pharmaceuticals Announces $22.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 26 Mar 2014
Kolltan Pharmaceuticals Obtains $60 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jan 2014
Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2013
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2013
Kolltan Pharmaceuticals Expands Senior Management Team, Appoints Jane Henderson as Senior Vice President & Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2012
Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Oct 2011
Phase III Trial of Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2010
Kolltan Pharmaceuticals Closes $10 Million Series B Related Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Sep 2009
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2009
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2009
Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
Diagnostics Oncology
 HSMN NewsFeed - 22 Dec 2008
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Sep 2008
KaloBios Raises $20 Million in Series D Venture Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2008
Lilly to Acquire SGX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Jun 2008
ArQule Announces Appointment of Brian Schwartz as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Nov 2007
Ambit Biosciences Raises Over $49 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jun 2007
Biodesix, Inc. Announces Breakthrough In Molecular Diagnostics For Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Ambit Biosciences Appoints Wendell Wierenga, Ph.D., as Executive Vice President of Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Receptor BioLogix Names Four New Senior Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Dec 2006
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2006
Receptor BioLogix Names Thomas A. Glaze Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 42

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 42 additional stories matching:
receptor tyrosine kinase
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!